--- title: "Vinod Khosla Says AI Is Creating a ‘Hyperabundance’ of New Drugs, but Testing Is Still ‘18th-Century’" type: "News" locale: "en" url: "https://longbridge.com/en/news/295770785.md" description: "Venture capitalist Vinod Khosla stated that AI has created a 'hyperabundance' of potential new drugs, but traditional animal testing remains outdated. He advocates for human-relevant testing methods, highlighting Vivodyne's technology to evaluate drugs using living human tissues at scale. This aligns with broader industry trends where companies like Anthropic, Takeda, Nvidia, and Eli Lilly are leveraging AI to accelerate drug discovery and development." datetime: "2026-08-13T08:33:50.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295770785.md) - [en](https://longbridge.com/en/news/295770785.md) - [zh-HK](https://longbridge.com/zh-HK/news/295770785.md) generator: "portal-rs" --- # Vinod Khosla Says AI Is Creating a ‘Hyperabundance’ of New Drugs, but Testing Is Still ‘18th-Century’ Venture capitalist **Vinod Khosla** said artificial intelligence (AI) is rapidly expanding drug discovery, but traditional testing methods have failed to keep pace with the technology’s progress. ## **AI and Human Tissue Drug Testing** On Wednesday, in a post on **X**, Khosla said AI has produced what he described as a "21st-century hyperabundance of potential new drugs and biological hypotheses," while drug testing still relies heavily on conventional animal studies. He argued that the industry needs a more human-relevant approach to evaluating potential treatments. "We are still using 18th-century style animal testing," Khosla wrote. He pointed to Vivodyne, a biotechnology company developing technology to test drugs using living human tissues at scale. "Instead, @Vivodyne is evaluating drugs in living human tissues at industrial scale," Khosla said. He also said he was excited to continue working with Vivodyne as the company develops its "Virtual Human" data center, which he said could eventually help researchers predict how patients will respond to treatments. > AI has created a 21st-century hyperabundance of potential new drugs and biological hypotheses, but we are still using 18th-century style animal testing. > > Instead, @Vivodyne is evaluating drugs in living human tissues at industrial scale. > > Excited to continue working with Vivodyne… pic.twitter.com/Xc1EwWQ5bB > > — Vinod Khosla (@vkhosla) August 12, 2026 **Read Also: World's First End-To-End AI Drug Developer To Power Into Black On Lucrative Partnerships** ## **AI Accelerates Drug Discovery and Healthcare** Earlier, **Anthropic**, **Takeda Pharmaceutical Co. Ltd.** (NYSE:TAK), **Nvidia Corp.** (NASDAQ:NVDA) and **Eli Lilly and Co.** (NYSE:LLY)  highlighted the growing role of AI in drug discovery and medical research. Anthropic launched Claude Science, an AI workbench that combined scientific literature analysis, computational biology, code generation and large-scale computing, with access to more than 60 scientific skills and connectors Takeda reported that its AI-developed psoriasis drug **zasocitinib** significantly outperformed **Bristol-Myers Squibb Co.**‘s (NYSE:BMY) Sotyktu in a Phase 3 trial, with more than 35% of patients achieving complete skin clearance at week 16. Meanwhile, Nvidia and Eli Lilly announced a $1 billion AI co-innovation lab aimed at combining AI with biological research to accelerate drug development. ***Disclaimer*:** *This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.* **Read Also: Tempus AI, Bristol Myers Squibb Expand AI-Driven Clinical Trial Efforts** *Photo courtesy: Shutterstock* ### Related Stocks - [LLY.US](https://longbridge.com/en/quote/LLY.US.md) - [NVDA.US](https://longbridge.com/en/quote/NVDA.US.md) - [NVDQ.US](https://longbridge.com/en/quote/NVDQ.US.md) - [ELIL.US](https://longbridge.com/en/quote/ELIL.US.md) - [NVDU.US](https://longbridge.com/en/quote/NVDU.US.md) - [ELIS.US](https://longbridge.com/en/quote/ELIS.US.md) - [NVD.US](https://longbridge.com/en/quote/NVD.US.md) - [NVDD.US](https://longbridge.com/en/quote/NVDD.US.md) - [NVDX.US](https://longbridge.com/en/quote/NVDX.US.md) - [NVDS.US](https://longbridge.com/en/quote/NVDS.US.md) - [NVDL.US](https://longbridge.com/en/quote/NVDL.US.md) - [NVDY.US](https://longbridge.com/en/quote/NVDY.US.md) - [LLYZ.US](https://longbridge.com/en/quote/LLYZ.US.md) - [LLYX.US](https://longbridge.com/en/quote/LLYX.US.md) - [NVDB.US](https://longbridge.com/en/quote/NVDB.US.md) - [NVDG.US](https://longbridge.com/en/quote/NVDG.US.md) - [NVDO.US](https://longbridge.com/en/quote/NVDO.US.md) - [NVDW.US](https://longbridge.com/en/quote/NVDW.US.md) - [NVYY.US](https://longbridge.com/en/quote/NVYY.US.md) - [NYYY.US](https://longbridge.com/en/quote/NYYY.US.md) - [DIPS.US](https://longbridge.com/en/quote/DIPS.US.md) - [MAGX.US](https://longbridge.com/en/quote/MAGX.US.md) - [07788.HK](https://longbridge.com/en/quote/07788.HK.md) - [07388.HK](https://longbridge.com/en/quote/07388.HK.md) - [09388.HK](https://longbridge.com/en/quote/09388.HK.md) - [4502.JP](https://longbridge.com/en/quote/4502.JP.md) - [ANTH.NA](https://longbridge.com/en/quote/ANTH.NA.md) - [TAK.US](https://longbridge.com/en/quote/TAK.US.md) - [BMY.US](https://longbridge.com/en/quote/BMY.US.md) - [TEM.US](https://longbridge.com/en/quote/TEM.US.md) - [NVD.DE](https://longbridge.com/en/quote/NVD.DE.md) - [CELG.RT.US](https://longbridge.com/en/quote/CELG.RT.US.md) ## Related News & Research - [NVDA: Record revenue and 70% growth outlook fueled by AI demand, with supply as the main constraint](https://longbridge.com/en/news/297098775.md) - [Nvidia’s Biggest Customers Face a Painful New AI Bill](https://longbridge.com/en/news/297062287.md) - [Nvidia to use Poolside deal to build alternative to Chinese AI, WSJ says](https://longbridge.com/en/news/296727449.md) - [Obesity Drug Alert: Eli Lilly Study Shows Sustained Zepbound Treatment Reduces Hospital Visits, Medical Costs](https://longbridge.com/en/news/297082109.md) - [VCI Global Announces Galatron AI Factory, a Modular AI Data Center Platform with Roadmap to 500MW of Compute Capacity | VCIG Stock News](https://longbridge.com/en/news/297046803.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**